赛诺医疗（688108）1月7日主力资金净卖出9752.29万元

Core Viewpoint - Sino Medical (688108) experienced a decline in stock price, closing at 21.89 yuan on January 7, 2026, down 3.14% with a turnover rate of 8.66% and a trading volume of 360,400 hands, amounting to a total transaction value of 802 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Sino Medical reported a main revenue of 364 million yuan, an increase of 14.24% year-on-year [3] - The net profit attributable to shareholders reached 21.12 million yuan, showing a significant increase of 293.46% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 13.91 million yuan, up 148.63% year-on-year [3] - In Q3 2025, the company achieved a quarterly main revenue of 123 million yuan, a year-on-year increase of 17.73% [3] - The quarterly net profit attributable to shareholders was 7.28 million yuan, reflecting a year-on-year increase of 150.51% [3] - The quarterly net profit after deducting non-recurring gains and losses was 5.93 million yuan, up 137.04% year-on-year [3] - The company's debt ratio stands at 30.4%, with financial expenses of 3.22 million yuan and a gross profit margin of 65.7% [3] Group 2: Market Activity - On January 7, 2026, the net outflow of main funds was 97.52 million yuan, accounting for 12.15% of the total transaction value, while retail investors saw a net inflow of 94.28 million yuan, representing 11.75% of the total transaction value [1] - The financing data indicates that on the same day, the financing buy amounted to 79.13 million yuan, while financing repayment was 97.58 million yuan, resulting in a net repayment of 18.46 million yuan [2] - The stock had a financing and securities lending balance of 736 million yuan [2] Group 3: Company Overview - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices, with product lines covering key areas such as cardiovascular, cerebrovascular, and structural heart disease interventions [3] - The company's core product is the BuMA biodegradable drug-coated coronary stent system, which is designed and developed in-house and holds international intellectual property rights [3]